Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

NCT03976856 ·Status: UNKNOWN ·Phase: PHASE1

The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

NCT04818983 ·Status: COMPLETED

Study of Poziotinib in Japanese Patients With NSCLC

NCT04402008 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

NCT06688656 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer

NCT00546130 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

NCT02496663 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NCT05991206 ·Status: RECRUITING

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

NCT04197076 ·Status: UNKNOWN

A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

NCT00144989 ·Status: COMPLETED ·Phase: PHASE3

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

NCT06585644 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326 ·Status: COMPLETED

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

NCT04453930 ·Status: UNKNOWN ·Phase: PHASE2

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

NCT05965102 ·Status: UNKNOWN ·Phase: PHASE1

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

NCT03684967 ·Status: WITHDRAWN ·Phase: PHASE2

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

NCT05962021 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307 ·Status: COMPLETED ·Phase: PHASE2

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

NCT02037997 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

NCT05445310 ·Status: RECRUITING ·Phase: PHASE2

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

NCT02031601 ·Status: UNKNOWN ·Phase: PHASE4

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

NCT05946460 ·Status: RECRUITING ·Phase: PHASE2

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00989690 ·Status: UNKNOWN ·Phase: PHASE3

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

NCT06951464 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

NCT02699606 ·Status: COMPLETED ·Phase: PHASE2

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04665856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3